Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.6, and our video podcast, CANCER BUZZ TV.



FDA Approves Sirolimus Protein-Bound Particles for PEComa

On Novemeber 23, 2021, the U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Read Aadi Bioscience, Inc.'s announcement.

Posted 11/23/2021